In my opinion, there appears to be two material issues with BDSI:
1. The pipeline has been valued at zero now because there are huge concerns about the ability of this company to get any non-BEMA product approved. The track record supports this valuation and frankly I think they need to take a long hard look at what they have acquired before moving forward. I certainly wouldn't move forward with Finn managing the development. The CTG trial seems to be a complete cluster. Following the cluster on Bunevail. Seems they need to figure the problem out quickly or Wall Street will pass them off as a one trick pony which can't manage studies.
2. Surprisingly the second problem magnifies the first. Despite what I believe to be a struggle with non BEMA R&D they don't have enough R&D going to be able to weather the storm of a failure. They are managing costs which is great but they need to feed the Wall Street beast. If practical, I would get multiple BEMA products in development asap so they can have other opportunities for investors to look to if one fails. Given the problem with 1, this is a catch 22. With Finn approaching 70, and a spotty track record at this time, they're in a bit of a bind.
Wouldn't hurt for management to attempt to assure the market that CTG is a hiccup in the life of BDSI and that the selloff is overdone. Assuming they believe this.
It would surprise me if Endo doesn't buy the marketing rights for Onsolis. I suspect a deal has already been worked out whereby Endo tells BDSI to agree on terms with MEDA which are acceptable to it and they will take the ball from there. Endo can use the same sales force to market this product as Bup.
What does the future hold? Sirgo is 61 and approaching retirement age. O'Donnell is 65. Finn is 66 and one has to wonder if he has the stamina to keep cranking at the rate it will require to move multiple products forward. They need to get younger or sell.